In conclusion, our study elucidates the oncogenic role of the ARAF p.S214C mutation in lung cancer and suggests the potential therapeutic avenue of its relationship with sorafenib, reinforcing the necessity of continuous research to refine patient stratification based on rare mutations. This evidence concerns the gene ARAF and lung cancer.